# Esketamine Nasal Spray in Real-World Settings in Treatment-Resistant Depression

> **NCT07146503** · — · RECRUITING · sponsor: **Riccardo Guglielmo** · enrollment: 100 (estimated)

## Conditions studied

- Depression and Quality of Life
- Treatment Resistant Depression (TRD)
- Anhedonia
- Apathy
- Anxiety
- Cognition
- Temperament
- Psychiatric Comorbidities

## Interventions

- **DRUG:** Esketamine (Intranasal Spray)

## Key facts

- **NCT ID:** NCT07146503
- **Lead sponsor:** Riccardo Guglielmo
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2022-11-01
- **Primary completion:** 2026-07
- **Final completion:** 2030-08
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07146503

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07146503, "Esketamine Nasal Spray in Real-World Settings in Treatment-Resistant Depression". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07146503. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*